SANGOMA TECHNOLOGIES CORP (SANG) Fundamental Analysis & Valuation

NASDAQ:SANG • CA80100R4089

Current stock price

4.24 USD
+0.16 (+3.92%)
Last:

This SANG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. SANG Profitability Analysis

1.1 Basic Checks

  • In the past year SANG has reported negative net income.
  • In the past year SANG had a positive cash flow from operations.
  • SANG had negative earnings in 4 of the past 5 years.
  • In the past 5 years SANG always reported a positive cash flow from operatings.
SANG Yearly Net Income VS EBIT VS OCF VS FCFSANG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -1.71%, SANG is in line with its industry, outperforming 45.65% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -2.22%, SANG is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
ROA -1.71%
ROE -2.22%
ROIC N/A
ROA(3y)-3.39%
ROA(5y)-6.47%
ROE(3y)-5.4%
ROE(5y)-10.77%
ROIC(3y)N/A
ROIC(5y)N/A
SANG Yearly ROA, ROE, ROICSANG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30

1.3 Margins

  • The Gross Margin of SANG (70.61%) is better than 91.30% of its industry peers.
  • SANG's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SANG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.76%
GM growth 5Y1.11%
SANG Yearly Profit, Operating, Gross MarginsSANG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. SANG Health Analysis

2.1 Basic Checks

  • SANG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SANG has less shares outstanding
  • The number of shares outstanding for SANG has been increased compared to 5 years ago.
  • SANG has a better debt/assets ratio than last year.
SANG Yearly Shares OutstandingSANG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
SANG Yearly Total Debt VS Total AssetsSANG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • SANG has an Altman-Z score of 1.10. This is a bad value and indicates that SANG is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 1.10, SANG perfoms like the industry average, outperforming 43.48% of the companies in the same industry.
  • The Debt to FCF ratio of SANG is 1.85, which is an excellent value as it means it would take SANG, only 1.85 years of fcf income to pay off all of its debts.
  • SANG has a better Debt to FCF ratio (1.85) than 60.87% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that SANG is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.09, SANG is in line with its industry, outperforming 52.17% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 1.85
Altman-Z 1.1
ROIC/WACCN/A
WACC8.67%
SANG Yearly LT Debt VS Equity VS FCFSANG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 0.87 indicates that SANG may have some problems paying its short term obligations.
  • SANG's Current ratio of 0.87 is on the low side compared to the rest of the industry. SANG is outperformed by 93.48% of its industry peers.
  • SANG has a Quick Ratio of 0.87. This is a bad value and indicates that SANG is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.71, SANG is not doing good in the industry: 91.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.71
SANG Yearly Current Assets VS Current LiabilitesSANG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. SANG Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 23.81% over the past year.
  • SANG shows a decrease in Revenue. In the last year, the revenue decreased by -8.93%.
  • SANG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.31% yearly.
EPS 1Y (TTM)23.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-8.93%
Revenue growth 3Y1.79%
Revenue growth 5Y19.31%
Sales Q2Q%-12.96%

3.2 Future

  • Based on estimates for the next years, SANG will show a very strong growth in Earnings Per Share. The EPS will grow by 35.09% on average per year.
  • SANG is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.00% yearly.
EPS Next Y-29.28%
EPS Next 2Y35.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-12.22%
Revenue Next 2Y-4%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SANG Yearly Revenue VS EstimatesSANG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
SANG Yearly EPS VS EstimatesSANG Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

3

4. SANG Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SANG. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SANG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SANG Price Earnings VS Forward Price EarningsSANG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SANG is valued cheaper than 100.00% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, SANG is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.78
EV/EBITDA 4.11
SANG Per share dataSANG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SANG's earnings are expected to grow with 35.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.09%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SANG Dividend Analysis

5.1 Amount

  • SANG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SANG Fundamentals: All Metrics, Ratios and Statistics

SANGOMA TECHNOLOGIES CORP

NASDAQ:SANG (4/29/2026, 8:00:01 PM)

4.24

+0.16 (+3.92%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryCommunications Equipment
Industry Strength74.02
Industry Growth49.25
Earnings (Last)02-04
Earnings (Next)05-07
Inst Owners33.1%
Inst Owner Change0%
Ins Owners27.35%
Ins Owner ChangeN/A
Market Cap141.11M
Revenue(TTM)219.70M
Net Income(TTM)-5.55M
Analysts82
Price Target7.74 (82.55%)
Short Float %0.47%
Short Ratio20.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-53.27%
Min EPS beat(2)-82.79%
Max EPS beat(2)-23.76%
EPS beat(4)1
Avg EPS beat(4)114.12%
Min EPS beat(4)-82.79%
Max EPS beat(4)595.05%
EPS beat(8)2
Avg EPS beat(8)24.93%
EPS beat(12)4
Avg EPS beat(12)-1.39%
EPS beat(16)5
Avg EPS beat(16)-265.1%
Revenue beat(2)0
Avg Revenue beat(2)-0.44%
Min Revenue beat(2)-0.46%
Max Revenue beat(2)-0.42%
Revenue beat(4)1
Avg Revenue beat(4)-0.74%
Min Revenue beat(4)-2.42%
Max Revenue beat(4)0.34%
Revenue beat(8)1
Avg Revenue beat(8)-2.01%
Revenue beat(12)3
Avg Revenue beat(12)-1.68%
Revenue beat(16)5
Avg Revenue beat(16)-0.76%
PT rev (1m)-5.39%
PT rev (3m)-4.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-6.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.64
P/FCF 5.78
P/OCF 4.3
P/B 0.56
P/tB N/A
EV/EBITDA 4.11
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)0.73
FCFY17.3%
OCF(TTM)0.99
OCFY23.26%
SpS6.6
BVpS7.51
TBVpS-0.61
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -1.71%
ROE -2.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.61%
FCFM 11.11%
ROA(3y)-3.39%
ROA(5y)-6.47%
ROE(3y)-5.4%
ROE(5y)-10.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.76%
GM growth 5Y1.11%
F-Score7
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 1.85
Debt/EBITDA 0.56
Cap/Depr 19.07%
Cap/Sales 3.82%
Interest Coverage N/A
Cash Conversion 79.63%
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.71
Altman-Z 1.1
F-Score7
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)22.92%
Cap/Depr(5y)19.53%
Cap/Sales(3y)4.2%
Cap/Sales(5y)3.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-29.28%
EPS Next 2Y35.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.93%
Revenue growth 3Y1.79%
Revenue growth 5Y19.31%
Sales Q2Q%-12.96%
Revenue Next Year-12.22%
Revenue Next 2Y-4%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-131.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2230.38%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.25%
FCF growth 3Y27.36%
FCF growth 5Y36.51%
OCF growth 1Y-5.99%
OCF growth 3Y25.66%
OCF growth 5Y36.31%

SANGOMA TECHNOLOGIES CORP / SANG Fundamental Analysis FAQ

What is the fundamental rating for SANG stock?

ChartMill assigns a fundamental rating of 3 / 10 to SANG.


What is the valuation status for SANG stock?

ChartMill assigns a valuation rating of 3 / 10 to SANGOMA TECHNOLOGIES CORP (SANG). This can be considered as Overvalued.


How profitable is SANGOMA TECHNOLOGIES CORP (SANG) stock?

SANGOMA TECHNOLOGIES CORP (SANG) has a profitability rating of 3 / 10.


Can you provide the financial health for SANG stock?

The financial health rating of SANGOMA TECHNOLOGIES CORP (SANG) is 3 / 10.


Can you provide the expected EPS growth for SANG stock?

The Earnings per Share (EPS) of SANGOMA TECHNOLOGIES CORP (SANG) is expected to decline by -29.28% in the next year.